JSJ. Ryan Shaw

J. Ryan Shaw

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


J. Ryan Shaw has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation and Extrapolation of a Tacrolimus Population Pharmacokinetic Model in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation Receiving Post‐Transplant Cyclophosphamide

    byĀ Riley M. Randolph, Tyler C. Dunlap, Stephany Gonzalez Tineo, Ryan M. Kemper, Jing Zhu, Kieran Collins, Yu Fei Wang, Pu Ouyang, Nichole Korpi‐Steiner, Eric Weimer, et al.

    Allogeneic hematopoietic cell transplant (allo‐HCT) is potentially curative for many hematologic diseases but complicated by acute graft‐versus‐host disease (aGVHD). While tacrolimus remains the cornerstone of aGVHD prophylaxis, regimens are increasingly including post‐transplant cyclophosphamide (PTCy). This single‐center study evaluated a previously published tacrolimus population pharmacokinetic (popPK) model developed from allo‐HCT recipients administered standard (tacrolimus plus methotrexate) aGVHD prophylaxis for generalizability to PTCy recipients. Adult allo‐HCT recipients treated with PTCy for aGVHD prophylaxis were included. Applicability of the established popPK model to the PTCy population was based on an evaluation of simulated to observed concentration ratios, and the distribution was interpreted with respect to a clinical equivalence range (0.8 to 1.25). The model was refit using data from both the standard and PTCy cohorts to describe the PK and support extrapolation to the PTCy population. Individual PK parameters from PTCy recipients were used to simulate steady‐state concentrations (C trough, ss ) using the current institutional weight‐based dosing strategy and the proposed model‐informed precision dosing (MIPD) algorithm. The proportion of patients predicted to experience a subtherapeutic C trough, ss (trough, ss values from 95 allo‐HCT recipients who received PTCy were included. The previous model did not successfully predict tacrolimus C trough, ss values among PTCy patients, but highlighted similarities between clearance in PTCy and standard aGVHD prophylaxis patients who received reduced‐intensity conditioning. Dosing simulations suggested a decreased proportion of PTCy patients would experience subtherapeutic tacrolimus C trough, ss with MIPD (3%) compared to conventional weight‐based dosing (23%).

  • Evaluating Day +90 Donor Chimerism as a Prognostic Marker of Clinical Outcomes Among Allogeneic Hematopoietic Cell Transplant Recipients Who Received Myeloablative Conditioning

    byĀ Sara Jubas, Kieran Collins, Kendall Obara, Hsuan-Hui (Grace) Liu, Ryan M. Kemper, Alexandra L.W. Kelley, Arushi Goel, Tyler C. Dunlap, Jing Zhu, Riley M. Randolph, et al.

  • A Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing

    byĀ Tyler C. Dunlap, Jing Zhu, Daniel L. Weiner, Ryan M. Kemper, Susanna C. DeVane, Feiyun Ma, Veronica Nguyen, James M. Coghill, Viet Dang, Tatjana Grgic, et al.

    Background Tacrolimus is a cornerstone of acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic cell transplant (allo-HCT) recipients. However, a narrow therapeutic index and high interindividual variability in pharmacokinetics (PK) make starting dose selection a major challenge in clinical practice. Methods Data from two PK studies conducted at the University of North Carolina Medical Center (UNCMC) were used to develop an oral tacrolimus population pharmacokinetic (popPK) model specific to adult allo-HCT recipients. Monte Carlo simulations were performed to compare the likelihood of achieving the UNCMC institutional target trough concentration range (ITR) (5–10 ng/mL) on the day of transplant (D0) under the current institutional dosing protocol, dosing recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC), and model-derived dosing recommendations. Results In total, 290 allo-HCT recipients contributed a total of 906 PK samples to the final analysis. A two-compartment popPK model adequately described the PK data. Population typical values of apparent clearance (TVCL/F) for 70 kg individuals receiving reduced intensity conditioning were 0.33 L/h/kg for CYP3A5 poor metabolizers (PMs) and 0.70 L/h/kg for intermediate and normal metabolizers (IMs and NMs). The probability of the population-level average D0 trough concentration being within the UNCMC ITR under the current UNCMC weight-based dosing protocol, CPIC-based, and model-derived dosing strategies were estimated to be 37%, 45%, and 76%, respectively. CYP3A5 IMs and NMs were predicted to require a 100% dose increase relative to CYP3A5 PMs. Conclusions We propose a new oral tacrolimus dosing strategy for adult allo-HCT recipients, which suggests the current weight-based dosing paradigm is insufficient. This new strategy includes CYP3A5 metabolizer phenotypes and conditioning regimen intensity, and could increase the percentage of allo-HCT recipients achieving target concentrations on D0. Clinical Trial Registration Number Clinicaltrials.gov NCT04645667


  • Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test‐Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients

    byĀ Tyler C. Dunlap, Daniel L. Weiner, Ryan M. Kemper, Miramar Kardouh, Susanna C. DeVane, Allison Symonds, J. Ryan Shaw, Paul M. Armistead, Jonathan R. Ptachcinski, Daniel J. Crona

    Busulfan is an alkylating agent used as part of conditioning chemotherapy regimens prior to allogeneic hematopoietic cell transplant (allo-HCT). Pharmacokinetic (PK)-guided test-dose strategies have been shown to improve the number of patients achieving busulfan exposure goals and improve clinical outcomes. However, current practices require extensive PK sampling. In this study, PK data were retrospectively collected from busulfan drug monitoring records from adult allo-HCT recipients who received once-daily intravenous busulfan at the University of North Carolina Medical Center (UNCMC). A population pharmacokinetic (popPK) model was developed to identify sources of interindividual variability and evaluate alternative PK sampling strategies. A 2-compartment model, with covariate effects of actual body weight and sex, best described the data. The typical value of clearance for an 83 kg male was estimated to be 11.21 L/h. Fifty-nine percent of allo-HCT recipients were estimated to have met the UNCMC institutional myeloablative conditioning (MAC) exposure goal based on model post hoc estimates of clearance using all PK samples obtained following MAC dosing. Fifty-seven percent of patients were estimated to have met this goal based on post hoc estimates using a single PK sample. Our results indicate once-daily, intravenous busulfan PK in adult allo-HCT recipients receiving MAC dosing can be reasonably described by a popPK model, and the use of a sparse PK sampling strategy may be feasible for determining target exposure attainment following MAC dosing. Use of a popPK model and sparse PK sampling strategy to carry out busulfan test-dose procedures could reduce health care costs and inconvenience to patients.


  • Open Access

    Utility of Urine Cultures During Febrile Neutropenia Workup in Hematopoietic Stem Cell Transplantation Recipients Without Urinary Symptoms

    byĀ Mya Tran, Shannon Palmer, Dominic T Moore, Luther Bartelt, Anne Friedland, Tatjana Grgic, Anne Lachiewicz, Jon Ptachcinski, Arlene Sena, Morgan Trepte, et al.

    The utility of obtaining screening urine cultures for febrile neutropenia (FN) during hematopoietic stem cell transplant (HCT) is unknown. In 667 adult HCT patients with FN, only 40 (6%) were found with bacteriuria. Antibiotics were modified in 3 patients (0.4%) based on urine cultures and none developed urinary-associated infectious complications.


  • Open Access

    Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion

    byĀ Kaci Shuman, Shannon Palmer, Brandi Anders, Dominic Moore, Jonathan Ptachcinski, Tatjana Grgic, Maurice Alexander, Lauren Hill, Anthony D. Sung, Paul M. Armistead, et al.


  • Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost

    byĀ Kevin Y. Chen, Tyler G. Bucci, J. Ryan Shaw, Maurice D. Alexander, Tatjana Grgic, Marcie Riches, Jonathan R. Ptachcinski


  • Open Access

    Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients

    byĀ Jing Zhu, Tejendra Patel, Jordan A. Miller, Chad D. Torrice, Mehak Aggarwal, Margaret R. Sketch, Maurice D. Alexander, Paul M. Armistead, James M. Coghill, Tatjana Grgic, et al.

    Tacrolimus exhibits high inter-patient pharmacokinetics (PK) variability, as well as a narrow therapeutic index, and therefore requires therapeutic drug monitoring. Germline mutations in cytochrome P450 isoforms 4 and 5 genes (CYP3A4/5) and the ATP-binding cassette B1 gene (ABCB1) may contribute to interindividual tacrolimus PK variability, which may impact clinical outcomes among allogeneic hematopoietic stem cell transplantation (HSCT) patients. In this study, 252 adult patients who received tacrolimus for acute graft versus host disease (aGVHD) prophylaxis after allogeneic HSCT were genotyped to evaluate if germline genetic variants associated with tacrolimus PK and pharmacodynamic (PD) variability. Significant associations were detected between germline variants in CYP3A4/5 and ABCB1 and PK endpoints (e.g., median steady-state tacrolimus concentrations and time to goal tacrolimus concentration). However, significant associations were not observed between CYP3A4/5 or ABCB1 germline variants and PD endpoints (e.g., aGVHD and treatment-emergent nephrotoxicity). Decreased age and CYP3A5*1/*1 genotype were independently associated with subtherapeutic tacrolimus trough concentrations while CYP3A5*1*3 or CYP3A5*3/*3 genotypes, myeloablative allogeneic HSCT conditioning regimen (MAC) and increased weight were independently associated with supratherapeutic tacrolimus trough concentrations. Future lines of prospective research inquiry are warranted to use both germline genetic and clinical data to develop precision dosing tools that will optimize both tacrolimus dosing and clinical outcomes among adult HSCT patients.


  • Drug–Drug Interaction Between Isavuconazole and Tacrolimus: Is Empiric Dose Adjustment Necessary?

    byĀ Wesley D. Kufel, Paul M. Armistead, Lindsay M. Daniels, Jonathan R. Ptachcinski, Maurice D. Alexander, J. Ryan Shaw

    A paucity of data currently exists regarding drug–drug interaction (DDI) with tacrolimus and isavuconazole coadministration. Current literature provides conflicting recommendations on whether an empiric tacrolimus dose reduction is necessary when coadministered with isavuconazole. A 47-year-old African American female with acute lymphoblastic leukemia underwent an allogenic stem cell transplant (alloSCT) and was subsequently placed on routine posttransplant therapy including tacrolimus for immunosuppression and posaconazole for antifungal prophylaxis. Tacrolimus was empirically dose reduced due to the expected DDI with posaconazole based on current recommendations. Due to a persistently prolonged QTc interval and need for mold coverage, antifungal prophylaxis was ultimately changed to isavuconazole at standard recommended dosing. Tacrolimus was empirically dose reduced by 40% based on limited available literature at the time; however, tacrolimus trough concentrations subsequently declined, requiring an increase in tacrolimus dose to maintain therapeutic trough concentrations. Adequate isavuconazole absorption was documented through pharmacokinetic and pharmacodynamic data by measuring an isavuconazole trough concentration and directly observing isavuconazole’s shortening effect on the QTc interval, respectively. Our experience in an alloSCT patient suggests that an empiric tacrolimus dose reduction is not required when isavuconazole is initiated, but close tacrolimus therapeutic drug monitoring should rather be performed to guide tacrolimus dosing.


  • Open Access

    Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation

    byĀ Jessica T. Stover, J. Ryan Shaw, Maragatha Kuchibhatla, Mitchell E. Horwitz, Ashley M. Engemann